These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 30689565

  • 41. Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.
    Doecke JD, Rembach A, Villemagne VL, Varghese S, Rainey-Smith S, Sarros S, Evered LA, Fowler CJ, Pertile KK, Rumble RL, Trounson B, Taddei K, Laws SM, Macaulay SL, Bush AI, Ellis KA, Martins R, Ames D, Silbert B, Vanderstichele H, Masters CL, Darby DG, Li QX, Collins S, AIBL Research Group.
    J Alzheimers Dis; 2018; 61(1):169-183. PubMed ID: 29171991
    [Abstract] [Full Text] [Related]

  • 42. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
    Sauvée M, DidierLaurent G, Latarche C, Escanyé MC, Olivier JL, Malaplate-Armand C.
    J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
    [Abstract] [Full Text] [Related]

  • 43. Decreasing body mass index is associated with cerebrospinal fluid markers of Alzheimer's pathology in MCI and mild dementia.
    Mathys J, Gholamrezaee M, Henry H, von Gunten A, Popp J.
    Exp Gerontol; 2017 Dec 15; 100():45-53. PubMed ID: 29054536
    [Abstract] [Full Text] [Related]

  • 44. Plasma Proteomic Profiles of Cerebrospinal Fluid-Defined Alzheimer's Disease Pathology in Older Adults.
    Dayon L, Wojcik J, Núñez Galindo A, Corthésy J, Cominetti O, Oikonomidi A, Henry H, Migliavacca E, Bowman GL, Popp J.
    J Alzheimers Dis; 2017 Dec 15; 60(4):1641-1652. PubMed ID: 29125490
    [Abstract] [Full Text] [Related]

  • 45. Linking CSF and cognition in Alzheimer's disease: Reanalysis of clinical data.
    Guhra M, Thomas C, Boedeker S, Kreisel S, Driessen M, Beblo T, Ohrmann P, Toepper M.
    Exp Gerontol; 2016 Jan 15; 73():107-13. PubMed ID: 26585048
    [Abstract] [Full Text] [Related]

  • 46. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
    Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosén E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttilä T, Wallin A, Jönhagen ME, Minthon L, Winblad B, Blennow K.
    JAMA; 2009 Jul 22; 302(4):385-93. PubMed ID: 19622817
    [Abstract] [Full Text] [Related]

  • 47. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA, Hewitt T, Croitoru-Lamoury J, Taddei K, Martins RN, Chew CS, Davies NN, Price P, Brew BJ.
    BMC Neurol; 2015 Apr 01; 15():51. PubMed ID: 25880550
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Influence of Allergy on Immunoglobulins and Amyloid-β in the Cerebrospinal Fluid of Patients with Alzheimer's Disease.
    Sarlus H, Eyjolfsdottir H, Eriksdotter M, Oprica M, Schultzberg M.
    J Alzheimers Dis; 2015 Apr 01; 48(2):495-505. PubMed ID: 26402013
    [Abstract] [Full Text] [Related]

  • 50. Memory Correlates of Alzheimer's Disease Cerebrospinal Fluid Markers: A Longitudinal Cohort Study.
    Reijs BLR, Ramakers IHGB, Köhler S, Teunissen CE, Koel-Simmelink M, Nathan PJ, Tsolaki M, Wahlund LO, Waldemar G, Hausner L, Vandenberghe R, Johannsen P, Blackwell A, Vanderstichele H, Verhey F, Visser PJ.
    J Alzheimers Dis; 2017 Apr 01; 60(3):1119-1128. PubMed ID: 28984585
    [Abstract] [Full Text] [Related]

  • 51. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia.
    Frölich L, Peters O, Lewczuk P, Gruber O, Teipel SJ, Gertz HJ, Jahn H, Jessen F, Kurz A, Luckhaus C, Hüll M, Pantel J, Reischies FM, Schröder J, Wagner M, Rienhoff O, Wolf S, Bauer C, Schuchhardt J, Heuser I, Rüther E, Henn F, Maier W, Wiltfang J, Kornhuber J.
    Alzheimers Res Ther; 2017 Oct 10; 9(1):84. PubMed ID: 29017593
    [Abstract] [Full Text] [Related]

  • 52. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort.
    Zwan M, van Harten A, Ossenkoppele R, Bouwman F, Teunissen C, Adriaanse S, Lammertsma A, Scheltens P, van Berckel B, van der Flier W.
    J Alzheimers Dis; 2014 Oct 10; 41(3):801-7. PubMed ID: 24705549
    [Abstract] [Full Text] [Related]

  • 53. Cerebrospinal Fluid Biomarkers for the Differential Diagnosis between Alzheimer's Disease and Frontotemporal Lobar Degeneration: Systematic Review, HSROC Analysis, and Confounding Factors.
    Rivero-Santana A, Ferreira D, Perestelo-Pérez L, Westman E, Wahlund LO, Sarría A, Serrano-Aguilar P.
    J Alzheimers Dis; 2017 Oct 10; 55(2):625-644. PubMed ID: 27716663
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56. Differential role of CSF fatty acid binding protein 3, α-synuclein, and Alzheimer's disease core biomarkers in Lewy body disorders and Alzheimer's dementia.
    Chiasserini D, Biscetti L, Eusebi P, Salvadori N, Frattini G, Simoni S, De Roeck N, Tambasco N, Stoops E, Vanderstichele H, Engelborghs S, Mollenhauer B, Calabresi P, Parnetti L.
    Alzheimers Res Ther; 2017 Jul 28; 9(1):52. PubMed ID: 28750675
    [Abstract] [Full Text] [Related]

  • 57. Alzheimer's Disease Biomarkers and Future Decline in Cognitive Normal Older Adults.
    Dumurgier J, Hanseeuw BJ, Hatling FB, Judge KA, Schultz AP, Chhatwal JP, Blacker D, Sperling RA, Johnson KA, Hyman BT, Gómez-Isla T.
    J Alzheimers Dis; 2017 Jul 28; 60(4):1451-1459. PubMed ID: 29036824
    [Abstract] [Full Text] [Related]

  • 58. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid.
    Forlenza OV, Aprahamian I, Radanovic M, Talib LL, Camargo MZ, Stella F, Machado-Vieira R, Gattaz WF.
    Bipolar Disord; 2016 Feb 28; 18(1):63-70. PubMed ID: 26876913
    [Abstract] [Full Text] [Related]

  • 59. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
    Somers C, Struyfs H, Goossens J, Niemantsverdriet E, Luyckx J, De Roeck N, De Roeck E, De Vil B, Cras P, Martin JJ, De Deyn PP, Bjerke M, Engelborghs S.
    J Alzheimers Dis; 2016 Aug 10; 54(1):383-95. PubMed ID: 27567807
    [Abstract] [Full Text] [Related]

  • 60. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
    Sunderland T, Linker G, Mirza N, Putnam KT, Friedman DL, Kimmel LH, Bergeson J, Manetti GJ, Zimmermann M, Tang B, Bartko JJ, Cohen RM.
    JAMA; 2016 Aug 10; 289(16):2094-103. PubMed ID: 12709467
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.